Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07304089) titled 'A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia' on Dec. 22, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Vima Therapeutics
Condition:
Dystonia
Intervention:
Drug: VIM0423
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 2026
Target Sample Size: 100
Countries of Recruitment:
United States
To know more, visit https://c...